Citius Pharmaceuticals (CTXR) Non-Current Debt (2011 - 2021)
Citius Pharmaceuticals' (CTXR) quarterly Non-Current Debt came in at $172970.0 in Q2 2021, up 5.1% YoY from $164583.0 in Q2 2020, and up 5.1% on a QoQ basis from $164583.0 in Q1 2021.
Citius Pharmaceuticals (CTXR) Non-Current Debt (2011 - 2021) Analysis & Trends
Citius Pharmaceuticals (CTXR) has 5 years of Non-Current Debt data on file, last reported at $172970.0 in Q2 2021.
- Quarterly Non-Current Debt rose 5.1% year-over-year to $172970.0 in Q2 2021, while the trailing twelve-month figure through Jun 2021 was $172970.0 (up 5.1% YoY) and the FY2020 annual result came in at $164583.0, changed N/A from the prior year.
- Non-Current Debt advanced to $172970.0 in Q2 2021, from $164583.0 in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $172970.0 in Q2 2021 to a low of $164583.0 in Q2 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 882.16 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.97 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 546.77 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 8.96 Bn |
| 10 | Citius Pharmaceuticals | 15.71 Mn | 15.71 Mn | 1.00 Mn | 6.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 172,970.00 |
| Mar 31, 2021 | 164,583.00 |
| Dec 31, 2020 | 164,583.00 |
| Sep 30, 2020 | 164,583.00 |
| Jun 30, 2020 | 164,583.00 |
| Sep 30, 2016 | 772,970.00 |
| Mar 30, 2016 | 772,970.00 |
| Jun 30, 2012 | 2,935.00 |
| Sep 30, 2011 | 18,493.00 |